# Red Arrow Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/red-arrow-therapeutics

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: https://redarrowtx.com
- Total disclosed funding: $4.4M
- Latest round: Seed (Apr 23, 2024)
- Investors on record: 4

## About

Based in Tokyo, Japan, and founded in 2021 by Chief Executive Officer Takuya Miyazaki, co-founders Horacio Cabral and Rika Tajima, Red Arrow Therapeutics, Inc. operates as a nanotechnology company developing an innovative drug delivery system with nanotechnology. In April 2024, Red Arrow Therapeutics, Inc. raised JPY 700 million in seed funding from Beyond Next Ventures, University of Tokyo Edge Capital Partners, Keio Innovation Initiative, Osaka University Venture Capital. 

Red Arrow Therapeutics, Inc. develops nanotechnology-based treatments for supporting patients with cancer treatment. The company’s technology includes small peptides to antibody full chains and cationic proteins to anionic proteins. It offers nanopolymer cytokine micelles, which get injected and affect pores in cancer microvessels to the tumor microenvironment. In addition, the firm’s pipeline includes RA-001 and RA-002 for converting cold tumors to hot, RA-003 for collaborating with pharma, and RA-004 (nucleic acids).

## Funding rounds

- Seed, Apr 23, 2024, $4.4M — University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Beyond Next Ventures, Keio Innovation Initiative

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Seed
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Seed
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Seed
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Seed